随机临床试验中质子与光子全盆腔放疗的稳健性比较
该研究在多中心随机临床试验框架下,纳入5例接受全盆腔放疗的高危前列腺癌患者,由5个光子中心独立制作光子计划,比较质子与光子计划在重复CT及稳健性场景下的剂量-体积指标。结果显示两种模态靶区覆盖均稳健,质子治疗显著降低肠道V35Gy和平均剂量以及膀胱平均剂量,且优势在名义、重算和不确定性场景中保持一致。
要点
- 质子全盆腔放疗靶区覆盖与光子相当,且在分次间变化下保持稳健。
- 质子治疗显著降低肠道V35Gy 11.2个百分点和肠道平均剂量13.9 Gy。
- 质子治疗膀胱平均剂量降低18.4 Gy,低中剂量正常组织暴露持续减少。
核心结论
- 质子全盆腔放疗在分次间变化下保持靶区覆盖稳健,并持续降低正常组织低中剂量暴露。
研究设计与样本
- 多中心随机临床试验框架下的稳健性比较研究,纳入5例在高危前列腺癌国家质子中心接受全盆腔放疗的患者。
- 由5个光子治疗中心独立创建比较光子计划,评估名义计划、每例两次重复CT重算计划及模拟几何不确定性的稳健性场景。
- 采用线性混合效应模型比较两种模态的靶区和正常组织剂量-体积指标,并考虑患者和中心变异性。
主要发现
- 两种模态在所有计划类型中靶区覆盖均持续稳健。
- 质子治疗使肠道V35Gy显著降低11.2个百分点(95% CI [4.1:18.4],p = 0.01)。
- 质子治疗使肠道平均剂量显著降低13.9 Gy(95% CI [9.5:18.4],p < 0.001)。
- 质子治疗使膀胱平均剂量降低18.4 Gy(p = 0.02)。
- 上述优势在名义、重算和不确定性场景计划中保持一致;高剂量正常组织指标未见一致的模态相关差异。
临床怎么用
- 对于高危前列腺癌全盆腔放疗,质子治疗可在保持靶区覆盖稳健的同时降低肠道和膀胱的低中剂量暴露。
局限性
- 研究仅纳入5例患者,样本量小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Proton therapy offers potentially improved normal tissue sparing compared to photon-based whole-pelvic radiotherapy (WPRT) for high-risk prostate cancer, but its sensitivity to anatomical and setup variations raises concerns about robustness. The aim of this study was - within the setting of a multicentre randomised clinical trial - to explore whether the dose-volume advantages of proton therapy persisted when subject to inter-fractional variation. MATERIALS AND METHODS: Five patients treated with WPRT at a national proton centre were included. Comparative photon plans were created independently by five photon therapy centres. Nominal proton and photon plans were evaluated alongside recalculated plans on two repeat computed tomography scans per patient and with robustness scenarios simulating geometric uncertainties. Dose-volume metrics for target volumes and normal tissues were compared between the two modalities using linear mixed effects models accounting for patient and centre variability. RESULTS: Target coverage was consistently robust for both modalities across all plan types. Proton therapy resulted in significantly reduced bowel V35Gy by 11.2 percentage points (95% CI [4.1:18.4], p = 0.01) and bowel mean dose by 13.9 Gy (95% CI [9.5:18.4], p < 0.001). Bladder mean dose was also lower with proton therapy (reduced by 18.4 Gy, p = 0.02). These advantages remained consistent across nominal, recalculated, and uncertainty scenario plans. No consistent modality-related differences were observed for high-dose normal tissue metrics. CONCLUSION: Within this robustness-inclusive multicentre comparison study, proton-based WPRT maintained target coverage comparable to photon therapy and consistently reduced low- and intermediate-dose exposure to normal tissues, while demonstrating preserved robustness under the influence of inter-fractional variation.
引用
- Tilbæk S, Petersen SE, Stolarczyk L, et al. A robustness-inclusive comparison of proton- versus photon-based whole-pelvic radiotherapy for prostate cancer within a randomised clinical trial. Radiother Oncol. 2026. PMID: 41611019. doi:10.1016/j.radonc.2026.111404
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。